Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorYoshino, T.
dc.contributor.authorCleary, J. M.
dc.contributor.authorVan Cutsem, E.
dc.contributor.authorMayer, Robert
dc.contributor.authorOhtsu, Atsushi
dc.contributor.authorShinozaki, E.
dc.contributor.authorArgilés Martinez, Guillem
dc.date.accessioned2021-10-19T10:19:26Z
dc.date.available2021-10-19T10:19:26Z
dc.date.issued2020-01
dc.identifier.citationYoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 Jan;31(1):88–95.
dc.identifier.issn0923-7534
dc.identifier.urihttp://hdl.handle.net/11351/6407
dc.descriptionChemotherapy-induced neutropenia; Metastatic colorectal cancer
dc.description.abstractBackground The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clinical outcomes. Patients and methods A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration–time curve (AUC) for FTD and TPI. We conducted a post hoc analysis using the entire RECOURSE population to determine the correlations between CIN and clinical outcome. We then carried out a similar analysis on the J003 trial to validate the results. Results In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS versus those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. Conclusions In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS versus those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAnnals of Oncology;31(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectRecte - Càncer - Quimioteràpia
dc.subjectCòlon - Càncer - Quimioteràpia
dc.subjectNeutropènia
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshNeutropenia
dc.titleNeutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.annonc.2019.10.005
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsneutropenia
dc.relation.publishversionhttps://doi.org/10.1016/j.annonc.2019.10.005
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Yoshino T, Ohtsu A] Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [Cleary JM, Mayer RJ] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. [Van Cutsem E] Division of Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium. [Shinozaki E] Department of Gastroenterology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. [Argilés G] Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid31912801
dc.identifier.wos000516712000014
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record